Biontech SE BNTX.OQ, BNTX.O is expected to show a fall in quarterly revenue when it reports results on May 5 for the period ending March 31 2025
The Mainz Rheinland-pfalz-based company is expected to report a 5.4% decrease in revenue to €177.398 million from €187.6 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biontech SE is for a loss of €2.09 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 22.6% in the last three months.
Wall Street's median 12-month price target for Biontech SE is $140.00, above its last closing price of $102.43.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.62 | 0.33 | 1.08 | Beat | 231.9 |
Sep. 30 2024 | -1.26 | -1.56 | 0.81 | Beat | 151.9 |
Jun. 30 2024 | -2.10 | -2.02 | -3.36 | Missed | -66.1 |
Mar. 31 2024 | -1.26 | -1.09 | -1.31 | Missed | -20.6 |
Dec. 31 2023 | 2.25 | 2.42 | 1.90 | Missed | -21.5 |
Sep. 30 2023 | -0.91 | -0.10 | 0.67 | Beat | 796.1 |
Jun. 30 2023 | -0.68 | -0.96 | -0.79 | Beat | 17.6 |
Mar. 31 2023 | -0.05 | 0.14 | 2.05 | Beat | 1,341.4 |
This summary was machine generated May 2 at 14:29 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。